EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

[18F]PI-2620 Tau PET signal across the aging and Alzheimer’s disease clinical spectrum

Christina B Young, Hillary Vossler, America Romero, Viktorija Smith, Jennifer Park, Alexandra N Trelle, Joseph R Winer, Edward N Wilson, Michael M Zeineh, Sharon J Sha, Mehdi Khalighi, Maya V Yutsis und 9 weitere

Imaging Neuroscience · 24.10.2024 · 2

DOI: 10.1162/imag_a_00329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Imaging Neuroscience, online erschienen am 24.10.2024. Verfasst von Christina B Young und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, United States. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[18F]PI-2620 is a second generation tracer that has shown high binding affinity for tau aggregation in Alzheimer’s disease (AD). However, [18F]PI-2620 signal in a large sample spanning the healthy aging and AD clinical spectrum as well as the stability of signal across different acquisition time windows has not yet been examined. Here, amyloid negative (Aβ-) cognitively unimpaired (CU; n = 49), amyloid positive (Aβ+) CU (n = 37), CU individuals with unknown amyloid status (n = 5), mild cognitive impairment (MCI; n = 14), dementia due to AD (n = 19), and non-AD neurodegenerative disorder (n = 54) participants were scanned with [18F]PI-2620 using a 45–75 min and/or 60–90 min acquisition time window. The impact of acquisition time on standardized uptake value ratio (SUVR) magnitude was first quantified with linear mixed models, and in participants and regions with high [18F]PI-2620 signal, SUVRs increased linearly up to 0.04 SUVR with each additional 5 min past injection time. We then accounted for differences in acquisition time using a voxel-wise correction approach and showed high correlations (all r’s ≥ 0.986) between SUVRs calculated from 45–75 min data and SUVRs from 60–90 min data that were interpolated to the 45–75 min scale in 15 participants who were scanned across both time windows. Using real and interpolated 45–75 min data, we next examined [18F]PI-2620 signal in Braak regions of interest and an off-target binding region (putamen) in Aβ- and Aβ+ CU, Aβ+ MCI, and Aβ+ AD dementia (n = 115) and showed that SUVRs in all Braak regions increased with greater disease severity. Within CU, higher Braak I SUVR was significantly associated with greater CSF pTau-181 (n = 35), and higher SUVRs were significantly associated with worse memory and language (n = 57). Thus, voxel-wise acquisition time corrections can be applied to combine [18F]PI-2620 datasets collected at different post-injection times, and once acquisition time is accounted for, [18F]PI-2620 signal shows the expected increases across the AD spectrum and can be used for detection of early tau elevations.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s disease[18F]PI-2620agingtau PET

Autor:innen und Institutionen

  • Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA, United States.
  • Department of Radiology, Stanford University School of Medicine, Palo Alto, CA, United States.
  • Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, United States.
  • Department of Epidemiology and Population Health, Stanford University School of Medicine, Palo Alto, CA, United States.
  • Department of Psychology, Stanford University, Stanford, CA, United States.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Young, C. B., Vossler, H., Romero, A., Smith, V., Park, J., Trelle, A. N., Winer, J. R., Wilson, E. N., Zeineh, M. M., Sha, S. J., Khalighi, M., Yutsis, M. V., Morales, A. P., Anders, D., Zaharchuk, G., Henderson, V. W., Andreasson, K. I., Wagner, A. D., Poston, K. L., …, & Mormino, E. C. (2024). [18F]PI-2620 Tau PET signal across the aging and Alzheimer’s disease clinical spectrum. Imaging Neuroscience, 2. https://doi.org/10.1162/imag_a_00329

Vancouver

Young CB, Vossler H, Romero A, Smith V, Park J, Trelle AN, et al. [18F]PI-2620 Tau PET signal across the aging and Alzheimer’s disease clinical spectrum. Imaging Neuroscience. 2024;2. doi:10.1162/imag_a_00329

BibTeX
@article{Young2024,
  author = {Young, Christina B and Vossler, Hillary and Romero, America and Smith, Viktorija and Park, Jennifer and Trelle, Alexandra N and Winer, Joseph R and Wilson, Edward N and Zeineh, Michael M and Sha, Sharon J and Khalighi, Mehdi and Yutsis, Maya V and Morales, Aimara P and Anders, David and Zaharchuk, Greg and Henderson, Victor W and Andreasson, Katrin I and Wagner, Anthony D and Poston, Kathleen L and Davidzon, Guido A and Mormino, Elizabeth C},
  title = {[18F]PI-2620 Tau PET signal across the aging and Alzheimer’s disease clinical spectrum},
  journal = {Imaging Neuroscience},
  year = {2024},
  volume = {2},
  doi = {10.1162/imag_a_00329}
}
Kostenlos starten →